Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial
Open Access
- 29 September 2020
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 36 (1) , 1-12
Abstract
Objective: To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment.Methods: Twenty‐four healthy volunteers receiving five daily oral doses of 10 mg ARI and 5 mg OLA in a crossover clinical trial were genotyped for 46 polymorphisms in 14 genes by qPCR. Drug plasma concentrations were measured by high‐performance liquid chromatography tandem mass spectrometry. Blood pressure (BP) and 12‐lead electrocardiogram were measured in supine position. AEs were also recorded.Results: ARI decreased diastolic BP on the first day and decreased QTc on the third and fifth day. OLA had a systolic and diastolic BP, heart rate and QTc lowering effect on the first day. Polymorphisms in ADRA2A, COMT, DRD3 and HTR2A genes were significantly associated to these changes. The most frequent adverse drug reactions (ADRs) to ARI were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to OLA. Additionally, HTR2A, HTR2C, DRD2, DRD3, OPRM1, UGT1A1 and CYP1A2 polymorphisms had a role in the development of ADRs.Conclusions: OLA induced more cardiovascular changes; however, more ADRs were registered to ARI. In addition, some polymorphisms may explain the difference in the incidence of these effects among subjects.Keywords
All Related Versions
Funding Information
- Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (PEJ‐2018‐TL/BMD‐11080)
This publication has 62 references indexed in Scilit:
- Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy VolunteersJournal of Clinical Psychopharmacology, 2016
- Evaluación de la causalidad en las comunicaciones de reacciones adversas a medicamentos. Algoritmo del Sistema Español de FarmacovigilanciaMedicina Clinica, 2016
- High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzymeThe Pharmacogenomics Journal, 2014
- Use of inotropes and vasopressor agents in critically ill patientsBritish Journal of Pharmacology, 2012
- Acetylcholine–dopamine balance hypothesis in the striatum: An updateGeriatrics & Gerontology International, 2010
- OlanzapineDrugs, 2001
- The Medical Dictionary for Regulatory Activities (MedDRA)Drug Safety, 1999
- Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapyAmerican Journal of Health-System Pharmacy, 1998
- AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS.Annals of Noninvasive Electrocardiology, 1997
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996